SciELO - Scientific Electronic Library Online

vol.34 issue2Quality control of enteral nutrition therapy in cancer patients at nutritional riskOral glutamine reduces myocardial damage after coronary revascularization under cardiopulmonary bypass. A randomized clinical trial author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Nutrición Hospitalaria

On-line version ISSN 1699-5198Print version ISSN 0212-1611


BURGOS-PELAEZ, Rosa et al. Cost analysis of home parenteral nutrition in Spain. Nutr. Hosp. [online]. 2017, vol.34, n.2, pp.271-276. ISSN 1699-5198.


Home parenteral nutrition (HPN) improves quality of life, allowing patients to receive nutrition at home and providing a social and labor integration to these patients.


To assess the direct costs of HPN in adult population in Spain.


A literature review of the records of HPN in Spain, carry out by NADYA-SENPE Group (years 2007-2014), was performed. The analysis included the evolution of: patients requiring HPN, number of episodes/patient, mean duration of episodes, description of delivery routes and complications rate. HPN consumption and cost were estimated. Patients were grouped according to their pathological group: benign and malignant. Direct costs (€, 2015) included were: parenteral nutrition bags, delivery sets and costs due to complications.


The number of patients who receive HPN has increased over years (2007: 133 patients; 2014: 220 patients). The average number of episodes per patient ranged from 1-2 episodes per year. The average duration of those episodes decreased (2007: 323 days; 2014: 202.8 days). Tunneled catheters were the most used and septic complications were the most common. The average annual cost per patient was estimated at € 8,393.30 and € 9,261.60 for benign and malign disease respectively. Considering that 220 patients required HPN in 2014, an annual cost of € 1,846.524.96 (€ 1,389,910.55 directly due to HPN) and € 2,037,551.90 (€ 1,580,937.50 directly due to HPN) was estimated for patients with benign and malignant pathologies respectively.


These results can be used to develop future economic evaluations on HPN and to establish efficient prioritization strategies to allocate available resources.

Keywords : Home parenteral nutrition; Complications; Venous access; Cost analysis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )